Compare · KNSA vs MEIP
KNSA vs MEIP
Side-by-side comparison of Kiniksa Pharmaceuticals International plc (KNSA) and MEI Pharma Inc. (MEIP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KNSA and MEIP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- KNSA is the larger of the two at $3.68B, about 14.5x MEIP ($253.7M).
- Over the past year, KNSA is up 64.5% and MEIP is up 44.8% - KNSA leads by 19.8 points.
- KNSA has hit the wire 12 times in the past 4 weeks while MEIP has been quiet.
- KNSA has more recent analyst coverage (6 ratings vs 5 for MEIP).
- Company
- Kiniksa Pharmaceuticals International plc
- MEI Pharma Inc.
- Price
- $47.90+2.07%
- $3.06+9.50%
- Market cap
- $3.68B
- $253.7M
- 1M return
- -16.97%
- -37.14%
- 1Y return
- +64.55%
- +44.79%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2003
- News (4w)
- 12
- 0
- Recent ratings
- 6
- 5
Kiniksa Pharmaceuticals International plc
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
MEI Pharma Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
Latest KNSA
- Director Quart Barry D converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Popovits Kimberly J converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- CHAIRMAN & CEO Patel Sanj K converted options into 900,000 units of Class A Ordinary Share (SEC Form 4)
- Director Mccain Tracey L converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Malley Thomas converted options into 2,799 units of Class A Ordinary Shares, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Levy Richard S converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 15% to 21,956 units (SEC Form 4)
- Director Cole G Bradley converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Baker Bros. Advisors Lp was granted 12,156 units of Class A Ordinary Shares (SEC Form 4)
- Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Latest MEIP
- MEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- New insider Schornstein Alexander claimed ownership of 4,365,472 shares (SEC Form 3)
- MEI Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'
- SEC Form EFFECT filed by MEI Pharma Inc.
- SEC Form 424B3 filed by MEI Pharma Inc.
- MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form S-3/A filed by MEI Pharma Inc.
- SEC Form 4 filed by Director Riezman Joshua
- SEC Form 3 filed by new insider Riezman Joshua